Bionano Reports Q2 2026 Results, Eliminates Debt
Bionano Genomics beat revenue expectations on strong clinical OGM adoption and retired all secured convertible debentures during the quarter.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day